版本:
中国

BRIEF-Genocea's Genital Herpes Immunotherapy GEN-003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

Sept 29 Genocea Biosciences, Inc. :

* Study achieved its primary endpoint

* Genocea's Genital Herpes Immunotherapy GEN003 demonstrates significant reduction of viral shedding in phase 2b clinical trial

* Phase 3 expected to start in 2h 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐